BIOMAT Database Logo BIOMAT Database Logo

Effect of recombinant human erythropoietin administration on immunological indices in patients undergoing chronic hemodialysis. 1993

N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.

In patients undergoing chronic hemodialysis, marked anemia may cause decreased immunological function. To improve this anemia, we investigated the effect on immunological indices of recombinant human erythropoietin (rHuEPO) administration in 24 hemodialysis patients (13 males and 11 females) with renal anemia complications. Their mean age was 54.9 +/- 14.8 years and the mean duration of dialysis was 100.5 +/- 54.9 months. The subjects were treated with rHuEPO for 12 months, which helped to maintain a hematocrit value elevated by 5% from the baseline. Cell-mediated immunity and humoral immunity were assessed prior to as well as throughout the treatment period. Of the total number of patients studied, the anemia of 16 improved while 8 did not show signs of sufficient improvement. The improved group showed an increase in in vitro lymphocytic response to phytohemagglutinin (PHA), CD4/CD8, CD16 and serum IgM levels, while the CD8 level decreased significantly. Improvement in the general physical condition with rHuEPO treatment appeared to be associated with the changes in immunological indices, but the precise mechanism remains obscure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
[Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients].
December 1991, Nihon rinsho. Japanese journal of clinical medicine,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Erythropoietic changes in chronic hemodialysis patients undergoing recombinant human erythropoietin therapy.
September 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Effect of recombinant human erythropoietin on anterior pituitary function in patients on chronic hemodialysis.
January 1991, Hormone research,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Effect of recombinant human erythropoietin on plasma von Willebrand factor in chronic hemodialysis patients.
October 1994, American journal of hematology,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
November 1991, Clinical nephrology,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
March 1995, Clinical nephrology,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
[Treatment of anemia in children undergoing chronic hemodialysis with recombinant human erythropoietin].
January 1994, Medicina,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
January 1993, Nephron,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
[Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
June 1990, Revista medica de Chile,
N Yorioka, and N Hamaguchi, and N Takasugi, and K Shigemoto, and S Harada, and K Fujiwara, and A Ishida, and T Maeda, and A Kawai, and M Yamakido
Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients.
August 1996, Kidney international,
Copied contents to your clipboard!